Circulating exosomal miRNAs and cancer early diagnosis

• L. Zhu ^[1] ; L. Zhao ^[1] ; Q. Wang ^[3] ; S. Zhong ^[1] ; X. Guo ^[4] ; Y. Zhu ^[2] ; J. Bao ^[1] ; K. Xu ^[4] ; S. Liu ^[1]
  1. [1] Zhejiang Chinese Medical University

     Zhejiang Chinese Medical University

     China

     
  2. [2] Beijing University of Chinese Medicine

     Beijing University of Chinese Medicine

     China

     
  3. [3] Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet, 141 86, Huddinge, Sweden
  4. [4] Centre for Cancer and Inflammation Research, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 24, Nº. 3 (Marzo), 2022, págs. 393-406
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • Microribonucleic acids (miRNAs) are small non-coding ribonucleic acids (ncRNAs), which can affect recognition of homologous sequences and interfere with transcription. It plays key roles in the initiation, development, resistance, metastasis or recurrence of cancers. Identifying circulatory indicators will positively improve the prognosis and quality of life of patients with early cancer. Previous studies have shown that miRNA is highly involved in cancer. In addition, miRNA derived from cancers can be encapsulated as exosomes and further extracted into circulatory systems to realize malignant functions. It indicates that circulating exosome-derived miRNAs have the potential to replace conventional biomarkers as cancer derived exosomes carrying miRNAs can be identified by specific markers and might be more stable and accurate for early diagnosis.